Articles By Jack Cush, MD
Half of Opioids Rx Come from 1% of MDs
The BMJ reports that while most US providers are cautious in their prescribing, half of opioid prescriptions are written by 1% of providers. Between 2003 and 2017, there was an annual average of 669495 providers prescribing 8.9 million opioid prescriptions.
Read Article
RheumNow Podcast- 2019 EULAR RA Guidelines (1.31.20)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Hormone Therapy for Postmenopausal Women
The NEJM weighs in on the problem of post-menopausal osteoporosis (OP) and tackles the use of hormonal therapy. The decline in estrogen after menopause may increase risks for osteoporosis, cardiovascular disease, and cognitive decline. The use of hormone replacement therapy (HRT) to obviate these issues may be primarily driven by hot flashes in postmenopausal women.1 Who may benefit from hormone therapy among postmenopausal women?
Read Article
Knee Replacements Last 25 Years
UK registry reports that greater than 80% of total knee replacements can last for 25 years.The outcomes regarding the duration and durability of knee arthroplasties is sketchy, with many orthopedists projecting a 15 to 20 year survivial. Hence the need for an appraisal of the data.
Read Article
Rheumatoid Arthritis Antibodies Linked With COPD
Women who were seropositive for anti-citrullinated protein antibodies (ACPA) and ultimately went on to develop rheumatoid arthritis (RA) were also at increased risk for being diagnosed with chronic obstructive pulmonary disease (COPD), analysis of data from the Nurses' Health Study showed.
Read Article
NSAIDs May Impair Healing if Taken Nightly
A new study in Scientific Reports suggest that circadian rhythms play an important role in wound healing, and that nonsteroidal anti-inflammatory drugs (NSAIDs) may be disruptive if taken at night given primary healing that occurs in a body at night.
Read Article
2019 EULAR Recommendations for the Management of Rheumatoid Arthritis
The 2019 update to the EULAR recommendations on the use of synthetic and biological disease-modifying antirheumatic drugs in rheumatoid arthritis (RA) have been published in Annals of Rheumatic Disease - highlighting the efforts of an international consensus committee effort. In the end, the task force put forth 5 overarching principles and 12 recommendations concerning use of conventional synthetic DMARDs, glucocorticoids, biological DMARDs, biosimilar DMARDs, and targeted synthetic DMARDs (the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib).
Read Article
RheumNow Podcast- A Good First Impression (1.24.20)
Dr Jack Cush comments on this week's journal articles, reviews and studies.
Read Article
QD Clinic - "Doc, When Can I Stop?"
QD Clinic - Lessons from the clinic. In this video: Patients stable on a biologic need guidance on when, and if, they can stop their biologic.
Read Article
Low Risk of Inflammatory Arthritis in Hidradenitis Suppurativa Patients
JAMA Dermatology reports that after the onset and diagnosis of hidradenitis suppurativa (HS), such patients have a higher risk of certain forms inflammatory arthritis.
Read Article
